Santarus, Inc. (SNTS) announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration of a December 2009 action date for an over-the-counter, or OTC, ZEGERID branded omeprazole/sodium bicarbonate product with the dosage strength of 20 mg of omeprazole. Schering-Plough submitted a New Drug Application in March 2008 seeking approval to sell ZEGERID in the U.S. OTC heartburn market.
Under the license agreement with Schering-Plough, Santarus is entitled to receive a $20-million milestone upon FDA approval of OTC ZEGERID, a low double-digit royalty on net sales of any OTC ZEGERID product, and may receive up to an additional $37.5 million in sales milestones.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.